Abbott Laboratories saw its shares fall by 8.1% in Thursday\u2019s afternoon session after the healthcare device and product giant reported second-quarter earnings that slightly beat expectations but failed to raise its full-year guidance. Investors appeared disappointed that the company maintained its adjusted EPS forecast for 2025 between $5.10 and $5.20 despite delivering a solid quarter.<\/p>\n\n\n\n
For Q2, Abbott posted adjusted earnings of $1.26 per share on revenue of $11.14 billion, surpassing analysts\u2019 estimates of $1.25 EPS and $11.07 billion in revenue. The Medical Devices segment was the standout performer, reporting 13.4% growth, particularly driven by strong sales of the FreeStyle Libre glucose monitoring system within its Diabetes Care division.<\/p>\n\n\n\n
While Abbott\u2019s 7.5% organic sales growth across its base business was impressive, the company\u2019s decision to keep full-year projections flat led to the market\u2019s sharp reaction. Analysts noted that investors had been hoping for a more bullish outlook following the strong Q2 performance, making the lack of guidance upgrade a potential signal of caution.<\/p>\n\n\n\n
The company has a track record of stability, with only one prior stock move exceeding 5% over the past year. Thursday\u2019s drop therefore reflects a shift in sentiment, even though the underlying fundamentals remain strong. Abbott\u2019s ability to drive consistent organic growth while navigating post-COVID diagnostic challenges supports its long-term positioning.<\/p>\n\n\n\n
Earlier in the year, Abbott shares gained 5.4% after Q1 earnings modestly exceeded expectations, with flat guidance helping to reassure investors amid macroeconomic uncertainty. During that quarter, the Medical Devices segment saw 12.6% organic growth, bolstered by demand for diabetes and cardiovascular technologies. However, the Diagnostics division dragged on performance due to a continued decline in COVID-19 test sales.<\/p>\n\n\n\n
Overall, Abbott\u2019s steady earnings, strong performance in key growth areas, and consistency in guidance reflect a cautious but stable approach in an unpredictable environment. For long-term investors, these short-term dips could present attractive entry points, particularly as the company continues to focus on innovation and market leadership in medical devices.<\/p>\n\n\n\n
Abbott shares are up 6.2% year-to-date but remain 14.1% below their 52-week high of $140.22 reached in March 2025. As of now, the stock is trading at $120.48 per share. Investors who purchased $1,000 in Abbott shares five years ago would currently hold approximately $1,214 in value, underlining its reputation as a stable, long-term growth stock.<\/p>\n\n\n\n
With solid fundamentals, improving demand in core segments, and a reliable track record, Abbott may still appeal to value investors \u2014 even if short-term sentiment remains cautious.<\/p>\n","protected":false},"excerpt":{"rendered":"
Solid Results Undermined by Unchanged 2025 Forecast Abbott Laboratories saw its shares fall by 8.1% in Thursday\u2019s afternoon session after the healthcare device and product giant reported second-quarter earnings that slightly beat expectations but failed to raise its full-year guidance. Investors appeared disappointed that the company maintained its adjusted EPS forecast for 2025 between $5.10<\/p>\n","protected":false},"author":5,"featured_media":6851,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[3403,4417,4420,4422,4423,1058,4416,4421,4419,4418],"class_list":{"0":"post-6850","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-2025-guidance","9":"tag-abbott-laboratories","10":"tag-diabetes-care","11":"tag-eps-forecast","12":"tag-freestyle-libre","13":"tag-healthcare-stocks","14":"tag-medical-devices","15":"tag-organic-sales","16":"tag-q2-earnings","17":"tag-stock-drop"},"_links":{"self":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts\/6850"}],"collection":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6850"}],"version-history":[{"count":1,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts\/6850\/revisions"}],"predecessor-version":[{"id":6852,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts\/6850\/revisions\/6852"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/media\/6851"}],"wp:attachment":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}